1X RIPA Buffer with HALT Protease and Phosphatase Inhibitors
Source:
Human
Form:
Liquid (sterile filtered)
Application Dilute:
ChIP: User Optimized, IP: User Optimized, WB: User Optimized
Application Notes:
W09-001-GJ5 has been tested by SDS-PAGE and western blot. Multi-purpose Hep-G2 Whole Cell Lysate is especially prepared as positive control for multiple assays including western blot, immunoprecipitation (IP), capture ELISA or other assays requiring nati
Cytotoxicity of PU+auranofin coatings.(A)Percent normalized hemolysis of hRBCs exposed to uncoated catheters, PU only, auranofin only (formulated at a 3 mg/mL auranofin coating concentration), PU+auranofin (formulated at 3, 10, 30, and 60 mg/mL auranofin coating concentrations) compared to negative controls of untreated hRBCs and a Triton X-100 incubated positive control.(B)Normalized HepG2 liver cell viability upon exposure to media incubated with uncoated catheters, PU only, and PU+auranofin (formulated at a 3 mg/mL auranofin coating concentration) catheters for 24 h. Data are shown as mean standard deviation. Statistical significance was evaluated using one-way ANOVA (n= 3) and is shown as ***p< 0.001 indicating statistical significance between the positive control (Triton X-100 with hRBCs) and other conditions tested. No statistical significance was noted between the other hemolysis conditions tested or between the different HepG2 viability conditions examined (p> 0.5). HepG2 (p/n W09-001-GJ5). Figure 8. PMID: 30873389.
* VAT and and shipping costs not included. Errors and price changes excepted
